MatthewAlexanderLunningDO

PubMed

• Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following fail...
  Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Future Oncology. 2024 Mar 28
• MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications.
  Chengfeng Bi, Yuhua Huang, Roshia Ali, Fang Wang, Xia Yang, Alyssa Bouska, Lu Xu, Xinbao Hao, Javeed Iqbal, Dennis D Weisenburger, Matthew A Lunning, Wing C Chan, Juli...> ;Haematologica. 2024 Mar 28
• Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS).
  Magdi Elsallab, Moataz Ellithi, Matthew A Lunning, Christopher D'Angelo, Jihyun Ma, Miguel-Angel Perales, Matthew J Frigault, Marcela V Maus> ;Blood. 2024 Mar 14
• 3 citations
  Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
  Michael D Jain, Miriam T Jacobs, Feng Gao, Loretta J Nastoupil, Jay Y Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwo...> ;Blood Advances. 2024 Feb 27
• 2 citations
  Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
  Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis, Alison Sehgal, S...> ;Blood. 2024 Feb 1
• PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
  Alderuccio, J., Reis, I., Hamadani, M., Nachiappan, M., Leslom, S., Kahl, B., Ai, W., Radford, J., Solh, M., Ardeshna, K., Hess, B., Lunning, M., Zinzani, P., Stathis,...> ;Clinical Cancer Research. 2024 Jan 5
• Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North Am...
  Barr, P. M., Barr, P. M., Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link, Me...> ;Journal of Hematology & Oncology. 2023 Dec 16
• Infectious complications among CD19 CAR-T cell therapy recipients: A single-center experience.
  Bryan Walker, Andrea J Zimmer, Erica J Stohs, Matthew Lunning, Elizabeth Lyden, Anum Abbas> ;Transplant Infectious Disease. 2023 Nov 1
• 1 citations
  Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A ph...
  Julie M Vose, Siddhartha Ganguly, Philip J Bierman, R Gregory Bociek, Matthew Lunning, Liz Lyden, Jane L Meza, Paolo F Caimi, James O Armitage> ;British Journal of Haematology. 2023 Jul 1
• 66 citations
  Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
  Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Blood. 2023 Apr 6
• 5 citations
  Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
  Jeremy S Abramson, Patrick B Johnston, Manali Kamdar, Sami Ibrahimi, Koji Izutsu, Jon Arnason, Bertram Glass, Pim Mutsaers, Matthew Lunning, Julia Braverman, Fei Fei L...> ;Blood Advances. 2022 Dec 13
• Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
  Juan P Alderuccio, Weiyun Z Ai, John Radford, Melhem Solh, Kirit M Ardeshna, Matthew A Lunning, Brian T Hess, Pier L Zinzani, Anastasios Stathis, Carmelo Carlo-Stella,...> ;Blood Advances. 2022 Aug 23
• 2 citations
  Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL.
  Zaid Al-Kadhimi, Samuel Pirruccello, Zartash Gul, Lori Maness-Harris, Vijaya Raj Bhatt, Krishna Gundabolu, Jane Yuan, Matthew Lunning, Gregory Bociek, Christopher D'An...> ;Bone Marrow Transplantation. 2022 Oct 1
• 163 citations
  Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with r...
  Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Il...> ;Lancet. 2022 Jun 18
• 62 citations
  Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
  Caron A Jacobson, Frederick L Locke, Long Ma, Julius Asubonteng, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David Bernard Miklos, Yi Lin, Miguel-Angel P...> ;Transplantation and Cellular Therapy. 2022 Sep 1
• 1 citations
  Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.
  N Nora Bennani, Aung M Tun, Kenneth R Carson, Jessica L Geiger, Lauren S Maeda, Kerry J Savage, Jim Rose, Lauren Pinter-Brown, Matthew A Lunning, Jeremy S Abramson, Na...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 May 1
• Autologous and allogeneic CAR T-cell therapies: spotlighting the "brain-to-vein" time.
  Matthew Lunning> ;Clinical Advances in Hematology & Oncology. 2022 Mar 1
• 15 citations
  The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy
  Paolo Caimi, Kirit M. Ardeshna, Erin Reid, Weiyun Z. Ai, Matthew A. Lunning, Jasmine Zain, Melhem Solh, Brad S. Kahl, Mehdi Hamadani> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Nov 12
• 1 citations
  Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.
  Mridula Krishnan, R. Gregory Bociek, Michelle A. Fanale, Swaminathan P. Iyer, Mary Jo Lechowicz, Philip J. Bierman, James O. Armitage, Matthew A. Lunning, Avyakta Kall...> ;Annals of Hematology. 2021 Oct 20
• Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.
  N Nora Bennani, Aung M Tun, Kenneth R Carson, Jessica L Geiger, Lauren S Maeda, Kerry J Savage, Jim Rose, Lauren Pinter-Brown, Matthew A Lunning, Jeremy S Abramson, Na...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Apr 1
• 8 citations
  American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Trans...
  Pashna N. Munshi, Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling, Brad S. Kahl, Mats Jerkeman, Mohamed A. Kharfan-Dabaja, Frederick ...> ;Transplantation and Cellular Therapy. 2021 Sep 1
• 17 citations
  ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
  Pashna N. Munshi, Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling, Brad S. Kahl, Mats Jerkeman, Mohamed A. Kharfan-Dabaja, Frederick ...> ;Bone Marrow Transplantation. 2021 Aug 20
• 15 citations
  Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
  Neha Mehta-Shah, Matthew A. Lunning, Alison J. Moskowitz, Adam M. Boruchov, Jia Ruan, Peggy Lynch, Paul A. Hamlin, John P. Leonard, Matthew J. Matasar, Patricia L. Mys...> ;American Journal of Hematology. 2021 Jul 12
• 32 citations
  Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
  Man Chun John Ma, Saber Tadros, Alyssa Bouska, Tayla Heavican, Haopeng Yang, Qing Deng, Dalia Moore, Ariz Akhter, Keenan Hartert, Neeraj Jain, Jordan Showell, Sreejoye...> ;Haematologica. 2021 Apr 1
• 12 citations
  Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
  Adam Zayac, Andrew M. Evens, Alexey V. Danilov, Stephen D. Smith, Deepa Jagadeesh, Lori A. Leslie, Catherine Wei, Seo-Hyun Kim, Seema Naik, Suchitra Sundaram, Nishitha...> ;Haematologica. 2021 Jul 1
• Join now to see all

Journal Articles

• Do You Know TAFRO?  
  James O Armitage, Matthew A Lunning, Blood

Lectures

• Driving Forces in Patient Selection for CAR T-Cell Therapy in Aggressive Lymphoma 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
• Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Targeting Oncoprotein Translation with Rocaglates in MYC-Driven Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all